Biohaven Ltd (BHVN) concluded trading on Thursday at a closing price of $15.82, with 7.7 million shares of worth about $121.81 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -69.83% during that period and on May 15, 2025 the price saw a loss of about -19.53%. Currently the company’s common shares owned by public are about 102.10M shares, out of which, 88.50M shares are available for trading.
Stock saw a price change of -21.88% in past 5 days and over the past one month there was a price change of -14.76%. Year-to-date (YTD), BHVN shares are showing a performance of -57.64% which decreased to -53.17% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $15.79 but also hit the highest price of $55.70 during that period. The average intraday trading volume for Biohaven Ltd shares is 1.62 million. The stock is currently trading -23.69% below its 20-day simple moving average (SMA20), while that difference is down -31.90% for SMA50 and it goes to -57.81% lower than SMA200.
Biohaven Ltd (NYSE: BHVN) currently have 102.10M outstanding shares and institutions hold larger chunk of about 90.73% of that.
The stock has a current market capitalization of $1.62B and its 3Y-monthly beta is at 3.87. It has posted earnings per share of -$9.37 in the same period. It has Quick Ratio of 2.33 while making debt-to-equity ratio of 0.14. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for BHVN, volatility over the week remained 10.23% while standing at 10.09% over the month.
Stock’s fiscal year EPS is expected to rise by 19.78% while it is estimated to increase by 15.93% in next year. EPS is likely to grow at an annualized rate of 18.68% for next 5-years, compared to annual growth of -49.78% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Deutsche Bank on February 11, 2025 offering a Buy rating for the stock and assigned a target price of $65 to it. Coverage by Jefferies stated Biohaven Ltd (BHVN) stock as a Buy in their note to investors on September 16, 2024, suggesting a price target of $57 for the stock. On September 04, 2024, Bernstein Initiated their recommendations, while on July 24, 2024, Morgan Stanley Initiated their ratings for the stock with a price target of $58. Stock get an Outperform rating from RBC Capital Mkts on February 16, 2024.
